These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Development and validation of a cisplatin dose-ototoxicity model. Dille MF, Wilmington D, McMillan GP, Helt W, Fausti SA, Konrad-Martin D. J Am Acad Audiol; 2012; 23(7):510-21. PubMed ID: 22992258 [Abstract] [Full Text] [Related]
3. ABR obtained from time-efficient train stimuli for cisplatin ototoxicity monitoring. Dille MF, Ellingson RM, McMillan GP, Konrad-Martin D. J Am Acad Audiol; 2013 Oct; 24(9):769-81. PubMed ID: 24224985 [Abstract] [Full Text] [Related]
4. OtoID: new extended frequency, portable audiometer for ototoxicity monitoring. Dille MF, Jacobs PG, Gordon SY, Helt WJ, McMillan GP. J Rehabil Res Dev; 2013 Oct; 50(7):997-1006. PubMed ID: 24301436 [Abstract] [Full Text] [Related]
8. Group-Wide, Prospective Study of Ototoxicity Assessment in Children Receiving Cisplatin Chemotherapy (ACCL05C1): A Report From the Children's Oncology Group. Knight KR, Chen L, Freyer D, Aplenc R, Bancroft M, Bliss B, Dang H, Gillmeister B, Hendershot E, Kraemer DF, Lindenfeld L, Meza J, Neuwelt EA, Pollock BH, Sung L. J Clin Oncol; 2017 Feb; 35(4):440-445. PubMed ID: 27937095 [Abstract] [Full Text] [Related]
9. Proposed comprehensive ototoxicity monitoring program for VA healthcare (COMP-VA). Konrad-Martin D, Reavis KM, McMillan G, Helt WJ, Dille M. J Rehabil Res Dev; 2014 Feb; 51(1):81-100. PubMed ID: 24805896 [Abstract] [Full Text] [Related]
13. Hearing loss before and after cisplatin-based chemotherapy in testicular cancer survivors: a longitudinal study. Haugnes HS, Stenklev NC, Brydøy M, Dahl O, Wilsgaard T, Laukli E, Fosså SD. Acta Oncol; 2018 Aug; 57(8):1075-1083. PubMed ID: 29384420 [Abstract] [Full Text] [Related]
15. Statistical model for prediction of hearing loss in patients receiving cisplatin chemotherapy. Johnson A, Tarima S, Wong S, Friedland DR, Runge CL. JAMA Otolaryngol Head Neck Surg; 2013 Mar; 139(3):256-64. PubMed ID: 23429908 [Abstract] [Full Text] [Related]
16. Diagnosis of hearing loss using automated audiometry in an asynchronous telehealth model: A pilot accuracy study. Brennan-Jones CG, Eikelboom RH, Swanepoel W. J Telemed Telecare; 2017 Feb; 23(2):256-262. PubMed ID: 27056904 [Abstract] [Full Text] [Related]
17. [The "Muenster classification" of high frequency hearing loss following cisplatin chemotherapy]. Schmidt CM, Bartholomäus E, Deuster D, Heinecke A, Dinnesen AG. HNO; 2007 Apr; 55(4):299-306. PubMed ID: 16437215 [Abstract] [Full Text] [Related]
18. Evoked otoacoustic emissions--an approach for monitoring cisplatin induced ototoxicity in children. Stavroulaki P, Apostolopoulos N, Segas J, Tsakanikos M, Adamopoulos G. Int J Pediatr Otorhinolaryngol; 2001 May 31; 59(1):47-57. PubMed ID: 11376818 [Abstract] [Full Text] [Related]